Brought to you by 
Avila grants Novartis an option to one of its programs
24 Aug 2009
Executive Summary
Avila Therapeutics (cancer and infectious and autoimmune diseases) has signed an option agreement with Novartis for the development of a covalent drug candidate program focused on protein silencing as a treatment for serious diseases.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Avila grants Novartis an option to one of its programs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice